A Study of Changes in the Prostate Following Androgen Deprivation to Investigate Therapy Response and Resistance in Clinical Prostate Cancer
- To identify the molecular and pathophysiological changes which occur during the early
stages of androgen deprivation (AD) and during emerging castration-resistant prostate
- To test functional imaging as a non-invasive tool to measure treatment response and
validate this using biological endpoints.
- To develop clinical models to predict how tumors will respond to AD and identify new
targets once AD fails.
- Group A: Patients likely to receive androgen deprivation (AD) as first-line therapy
undergo blood and prostate biopsy sample collection before and after treatment on days
0 and 14 or 90. Patients receive an androgen receptor inhibitor followed by maintenance
with a gonadotropin-releasing hormone analogue beginning on day 0. Patients also
undergo diffusion-weighted MRI, MR spectroscopic imagining, quantitative T1W mapping,
and T1W perfusion sequence.
- Group B: Patients already receiving AD undergo blood and prostate biopsy sample
collection within 4 weeks of diagnosis of castration-resistant prostate cancer and
before initiating any second-line therapy.
Blood and tissue samples are assessed via DNA and RNA genetic analysis, gene expression
studies, and comparative genomic hybridization to identify novel markers of androgen
response and resistance.
Peer Reviewed and Funded or Endorsed by Cancer Research UK.
Allocation: Non-Randomized, Primary Purpose: Treatment
Identification of molecular and pathophysiological changes
Vincent Gnanapragasam, MD
Cancer Research UK at Cambridge Research Institute